The Two Sides Of Dual-Class Shares It sounds too good

New Post Public Reply Private Reply Replies (0) Message Board
NITE


The Two Sides Of Dual-Class Shares
It sounds too good to be true: own a small portion of a company's total stock, but get most of the voting power. That's the truth behind dual-class shares. They allow shareholders of non-traded stock to control terms of the company in excess of the financial stake. While many investors would like to eliminate dual-class shares, there are several hundred companies in the United States with dual "A" and "B" listed shares, or even multiple class listed shares. So, the question is, what's the impact of dual-class ownership on a company's fundamentals and performance? (To learn more, see The ABCs Of Mutual Fund Classes.)



What Are Dual-Class Shares?
When the Internet company Google went public, a lot of investors were upset that it issued a second class of shares to ensure that the firm's founders and top executives maintained control. Each of the Class B shares reserved for Google insiders would carry 10 votes, while ordinary Class A shares sold to the public would get just one vote. (To learn more, see When Insiders Buy, Should Investors Join Them?)

Designed to give specific shareholders voting control, unequal voting shares are primarily created to satisfy owners who don't want to give up control, but do want the public equity market to provide financing. In most cases, these super-voting shares are not publicly traded and company founders and their families are most commonly the controlling groups in dual-class companies.

Who Lists Them?
The New York Stock Exchange allows U.S. companies to list dual-class voting shares. Once shares are listed, however, companies cannot reduce the voting rights of the existing shares or issue a new class of superior voting shares. (For more information, see The NYSE And Nasdaq: How They Work.)

Many companies list dual-class shares. Ford's dual-class stock structure, for instance, allows the Ford family to control 40% of shareholder voting power with only about 4% of the total equity in the company. Berkshire Hathaway Inc., which has Warren Buffett as a majority shareholder, offers a B share with 1/30th the interest of its A-class shares, but 1/200th of the voting power. Echostar Communications demonstrates the extreme power that can be had through dual-class shares: founder and CEO Charlie Ergen has about 5% of the company's stock, but his super-voting class-A shares give him a whopping 90% of the vote.

Good or Bad?
It's easy to dislike companies with dual-class share structures, but the idea behind it has its defenders. They say that the practice insulates managers from Wall Street's short-term mindset. Founders often have a longer term vision than investors focused on the most recent quarterly figures. Since stock that provides extra voting rights often cannot be traded, it ensures the company will have a set of loyal investors during rough patches. In these cases, company performance may benefit from the existence of dual-class shares.

With that said, there are plenty of reasons to dislike these shares. They can be seen as downright unfair. They create an inferior class of shareholders and hand over power to a select few, who are then allowed to pass the financial risk onto others. With few constraints placed upon them, managers holding super-class stock can spin out of control. Families and senior managers can entrench themselves into the operations of the company, regardless of their abilities and performance. Finally, dual-class structures may allow management to make bad decisions with few consequences.
Hollinger International presents a good example of the negative effects of dual-class shares. Former CEO Conrad Black controlled all of the company's class-B shares, which gave him 30% of the equity and 73% of the voting power. He ran the company as if he were the sole owner, exacting huge management fees, consulting payments and personal dividends. Hollinger's board of directors was filled with Black's friends who were unlikely to forcefully oppose his authority. Holders of publicly traded shares of Hollinger had almost no power to make any decisions in terms of executive compensation, mergers and acquisitions, board construction poison pills or anything else for that matter. Hollinger's financial and share performance suffered under Black's control. (To learn more, see Mergers And Acquisitions: Understanding Takeovers.)

Academic research offers strong evidence that dual-class share structures hinder corporate performance. A Wharton School and Harvard Business School study shows that while large ownership stakes in managers' hands tend to improve corporate performance, heavy voting control by insiders weakens it. Shareholders with super-voting rights are reluctant to raise cash by selling additional shares--that could dilute these shareholders' influence. The study also shows that dual-class companies tend to be burdened with more debt than single-class companies. Even worse, dual-class stocks tend to under-perform the stock market.

The Bottom Line
Not every dual-class company is destined to perform poorly--Berkshire Hathaway, for one, has consistently delivered great fundamentals and shareholder value. Controlling shareholders normally have an interest in maintaining a good reputation with investors. Insofar as family members wield voting power, they have an emotional incentive to vote in a manner that enhances performance. All the same, investors should keep in mind the effects of dual-class ownership on company fundamentals.
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Melrose Fire Station Reaches Steel Topping Milestone

Updated Category News Views 4

Metal and Milestones: A New Era for Melrose Rolling into Melrose, Massachusetts, there's some serious action kicking off with the new Fire Engine 2 Station reaching a steel topping milestone. This phase isn't just about slapping on another beam; it's the crescendo of diligent teamwork from all the hands involved—from CTA Construction Managers to the clout of Ironworkers...

Continue Reading
Salveo Home Care Faces Class Action Over Labor Violations

Updated Category News Views 5

Another Company Lands in Hot Water Alright, it looks like Salveo Home Care is in the spotlight for all the wrong reasons. The home care provider—which should have been minding its P's and Q's—is now facing a class action suit. Why, you ask? Well, for allegedly skimping on wages and dodging legal obligations that leave their employees hanging dry. The Allegations are...

Continue Reading
Fuse Oncology Showcases New iRT Workflow at ASTRO

Updated Category News Views 4

Revolutionizing Charge Capture in Oncology Fuse Oncology's latest showcase at the ASTRO 2026 Annual Meeting isn't just about flashy presentations—it's looking to change how radiation oncology departments handle complex workflows. If you've ever delved into the maze of oncology billing, you know it's rife with opportunities for errors and inefficiencies. Skip one charge,...

Continue Reading
IASO's FUCASO Shows Robust Results in 2026 Study

Updated Category News Views 7

IASO's Groundbreaking Results Stir Ripples in Oncology Folks, let me paint the picture here with the mighty, nitty-gritty details straight from the heart of China. The 2026 IMS Annual Meeting held a gem that could redefine how investors see the course of hematologic malignancy treatments. IASO Bio dropped some heavy data, showing their fine product, FUCASO, in a...

Continue Reading
Revamping Children's Radiotherapy: Leo Cancer Care's Vision

Updated Category News Views 5

The latest buzz in pediatric radiotherapy is shaking things up, and it’s all thanks to a game-changing shift in how treatment is delivered to kids. We're eyeballing Leo Cancer Care's innovative approach that might just redefine how these young patients face their battles. Standing Tall: A New Chapter in Proton Therapy In June, Stanford Medicine dished out the first...

Continue Reading
Quay Shines in 2026 Prescription Sunglasses Lineup

Updated Category News Views 5

Spotlight on Quay: A Fashion-Forward Prescription Glasses that make you look good and actually correct your vision? That's the holy grail right there. Consumer365 just put Quay front and center in their 2026 rundown of the best prescription sunglasses out there. Let's break this down and see what's got folks buzzing. Diving into Style and Substance Now, if you're like me,...

Continue Reading
AI Memory Growth Pushes Limits at GMIF2026 Summit

Updated Category News Views 4

The Memory and Storage Race in the AI Era The 5th GMIF2026 Innovation Summit wrapped up in Shenzhen, and boy, was it a heavyweight bout. You could practically feel the tension in the room as industry giants sparred over the future of memory and storage in AI. This wasn't just another trade show pow-wow; this was a strategic chess match over where AI infrastructure is...

Continue Reading
DKS Facing Class Action Over Stock Slump Allegations

Updated Category News Views 3

A Burst Bubble at DICK'S Sporting Goods Grit your teeth and hang on—DICK'S Sporting Goods has stumbled, and investors are supposed to just weather the storm. From September 8, 2025, through August 24, 2026, if you held DICK'S shares, you've got some explaining to do, or at least you better start reading the fine print. Take note, folks: the deadline to file for lead...

Continue Reading
Synagro Technologies Faces Lawsuit Over Unpaid Expenses

Updated Category News Views 6

Another Day, Another Lawsuit in Corporate America When it rains, it pours, especially in the corporate world where companies occasionally seem to forget they're playing with other people's livelihoods. Now, it's Synagro Technologies, Inc. facing the music. The company is under fire from Blumenthal Nordrehaug Bhowmik De Blouw LLP, a law firm well-versed in employee rights...

Continue Reading
Leo Cancer Care's Upright Radiotherapy Milestone

Updated Category News Views 4

Upright Radiotherapy: Breaking Tradition in Cancer Care Here's a twist in the world of cancer treatment folks weren't exactly expecting. Leo Cancer Care has flipped the script by taking radiotherapy from a concept to an actual clinical reality with their Upright Platform. Yes, we're talking about standing up while getting treated, and it's not just a gimmick—it's a game...

Continue Reading

Top 5 Most Recently Viewed Articles

Vaccinex Unveils Efficacy Insights for Pepinemab in Alzheimer’s Study

Updated Category News Views 71

Vaccinex Provides Update on Pepinemab Study for Alzheimer’s Disease ROCHESTER, N.Y. — Vaccinex, Inc. (NASDAQ: VCNX), a forward-thinking biotechnology firm, is making significant strides in the treatment of Alzheimer's disease (AD) and cancer. The company is focused on a unique approach through the inhibition of Semaphorin 4D (SEMA4D). Recently, it was announced that...

Continue Reading
Legal Inquiry into Netflix, Inc. (NFLX) Attracts Investor Attention

Updated Category News Views 287

Understanding the Investigation into Netflix, Inc. Recently, the law firm Robbins Geller Rudman & Dowd LLP has initiated a formal investigation into Netflix, Inc. (NASDAQ: NFLX). This inquiry primarily focuses on potential violations of U.S. federal securities laws that may have occurred within the company. The Implications for Investors This investigation comes at a...

Continue Reading
Norway's Wealth Fund Expands Portfolio with London Investment

Updated Category News Views 221

Norway's Sovereign Wealth Fund Takes Bold Step in London Norway's sovereign wealth fund, expertly managed by Norges Bank Investment Management, has recently made headlines with its strategic acquisition of a 25% stake in a notable portfolio of office and retail properties located in London's prestigious Mayfair district. Significant Investment in a Prime Location This...

Continue Reading
Exagen Inc. Announces New Biomarkers and Financial Success

Updated Category News Views 291

Exagen Inc. Introduces Groundbreaking Biomarkers for Autoimmune Diseases Innovative testing aims to enhance patient diagnosis and care Exagen Inc. (Nasdaq: XGN), a pioneering company in autoimmune testing, has achieved a significant milestone by receiving conditional approval from the New York State Department of Health for its advanced assays to diagnose systemic lupus...

Continue Reading
Pacaso's Financial Growth in 2025: A Closer Look At Results

Updated Category News Views 1306

Pacaso Shows Promising First Half Financial Performance Pacaso, the innovative platform for co-owned luxury vacation homes, has recently shared its financial results for the first half of 2025, demonstrating strong stability and improved efficiency despite a challenging broader housing market. The company reported an impressive adjusted gross profit while managing to...

Continue Reading